Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

Intravenous administration of80mg ofrecombinant tissue plasminogen activator (rt- PA,40,20,and20mg insuccessive hours) andstreptokinase (SK,1.5million units over1hr) was compared inadouble-blind, randomized trial in290patients withevolving acutemyocardial infarc- tion. Thesepatients entered thetrial within 7hroftheonsetofsymptomsandunderwent baseline coronaryarteriography before thrombolytic therapy was instituted. Ninety minutes after thestart of thrombolytic therapy, occluded infarct-related arteries hadopened in62%of113patients inthert-PA and31%of119patients intheSK group(p<.001). Twice asmany occluded infarct-related arteries opened after rt-PA compared withSKatthetimeofeachofsevenangiograms obtained during thefirst 90minafter commencing thrombolytic therapy. Regardless ofthetimefromonsetofsymptomsto treatment, more arteries wereopened after rt-PA thanSK.Thereduction incirculating fibrinogen and plasminogen andtheincrease incirculating fibrin split products at3and24hrweresignificantly less in patients treated withrt-PA thaninthose treated withSK(p<.001). Theoccurrenceofbleeding events, administration ofblood transfusions, andreocclusion oftheinfarct-related artery was comparable inthe twogroups.Thus, inpatients with acutemyocardial infarction, rt-PA elicited reperfusion intwice as many occluded infarct-related arteries ascompared withSKateachofsevenserial observations during thefirst 90minafter onsetoftreatment. Circulation 76,No.1,142-154, 1987.

[1]  B. Pitt,et al.  A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. , 1986, The New England journal of medicine.

[2]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[3]  K. Rentrop,et al.  Thrombolytic therapy in patients with acute myocardial infarction. , 1985, Circulation.

[4]  E. Falk Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[5]  H. Lijnen,et al.  Coronary thrombolysis indogswithintravenously administered humanpro-urokinase , 1985 .

[6]  F. Sheehan,et al.  Effect of interventions in salvaging left ventricular function in acute myocardial infarction: a study of intracoronary streptokinase. , 1983, The American journal of cardiology.

[7]  M. Verstraete,et al.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. , 1983, The Journal of clinical investigation.

[8]  E L Bolson,et al.  Experimental Validation of Quantitative Coronary Arteriography for Determining Pressure-Flow Characteristics of Coronary Stenosis , 1982, Circulation.

[9]  E. Bolson,et al.  Experimental Validation ofQuantitative Coronary Arteriography forDetermining Pressure-Flow Characteristics ofCoronary Stenosis , 1982 .

[10]  E. Bolson,et al.  Quantitative Coronary Angiography: Measurement of the "Critical" Stenosis in Patients with Unstable Angina and Single-Vessel Disease Without Collaterals , 1979, Circulation.